Literature DB >> 28685080

Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis.

Li Li1, Yahua Zhong1, Hongyan Zhang1, Haijun Yu1, Yong Huang1, Zheng Li1, Gaili Chen1, Xinying Hua1.   

Abstract

Triple-negative breast cancer (TNBC), a unique subtype of breast cancer, which is resistant to endocrine and targeted therapy, usually relapses early, progresses rapidly and is associated with a poor prognosis. Epidemiological investigations focusing on the association between risk factors and the onset of TNBC demonstrated that the incidence of TNBC exhibits a significant correlation with anthropometric, geographical and demographic parameters. The aim of the present systematic review and meta-analysis was to evaluate the strength of the association between the use of oral contraceptives (OCs) and TNBC. Two databases (PubMed Central/PubMed, Web of Science) and secondary references were searched to identify studies meeting the priorly established inclusion criteria. Case-control studies published between January, 2005 and March, 2016 were searched using the key words (triple-negative breast cancer OR basal-like) AND (oral contraceptives). Finally, 9 eligible articles using as control other subtypes of invasive breast cancer and 7 articles using a healthy population as control were incorporated in the meta-analysis. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using fixed- or random-effects models according to the heterogeneity between studies. The case-control comparison using other subtypes of breast cancer as the control arm exhibited a significant association between OC use and TNBC (OR = 1.31, 95% CI = 1.18-1.45; Z=5.26, P<0.00001). These results were further confirmed by the case-control comparison using the healthy population as the control arm (OR = 1.21, 95% CI = 1.01-1.46; Z=2.04, P=0.04). The present meta-analysis indicated that women who use OCs have a greater risk of TNBC compared with women who do not. This conclusion prompts that women who used OCs should be examined more closely in population screenings of breast cancer, as they may benefit from prevention and early detection strategies.

Entities:  

Keywords:  molecular marker; oral contraceptives; risk factor; triple-negative breast cancer

Year:  2017        PMID: 28685080      PMCID: PMC5492671          DOI: 10.3892/mco.2017.1259

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  35 in total

1.  High-dose chemotherapy for triple negative breast cancer.

Authors:  U De Giorgi; G Rosti; L Frassineti; B Kopf; N Giovannini; F Zumaglini; M Marangolo
Journal:  Ann Oncol       Date:  2006-09-13       Impact factor: 32.976

Review 2.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

Authors:  James D Brenton; Lisa A Carey; Ahmed Ashour Ahmed; Carlos Caldas
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

3.  Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers.

Authors:  Piyush B Gupta; David Proia; Oya Cingoz; Janusz Weremowicz; Stephen P Naber; Robert A Weinberg; Charlotte Kuperwasser
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

4.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

5.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

6.  Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

Review 8.  Triple-negative/basal-like breast cancer: review.

Authors:  Emad A Rakha; Ian O Ellis
Journal:  Pathology       Date:  2009-01       Impact factor: 5.306

9.  Risk factors for triple-negative breast cancer in women under the age of 45 years.

Authors:  Jessica M Dolle; Janet R Daling; Emily White; Louise A Brinton; David R Doody; Peggy L Porter; Kathleen E Malone
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-31       Impact factor: 4.254

Review 10.  What is triple-negative breast cancer?

Authors:  William J Irvin; Lisa A Carey
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

View more
  11 in total

1.  Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.

Authors:  Nicole C Lorona; Linda S Cook; Mei-Tzu C Tang; Deirdre A Hill; Charles L Wiggins; Christopher I Li
Journal:  Horm Cancer       Date:  2019-04-15       Impact factor: 3.869

2.  HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling.

Authors:  Jie Bai; Wei-Bin Chen; Xiao-Yu Zhang; Xiao-Ning Kang; Li-Jun Jin; Hui Zhang; Zun-Yi Wang
Journal:  World J Stem Cells       Date:  2020-01-26       Impact factor: 5.326

3.  Breast Cancer Risk Factors: a Cross- Cultural Comparison between the West and the East

Authors:  Lina Kurdahi Badr; Laura Bourdeanu; Manal Alatrash; Garine Bekarian
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24

Review 4.  Epidemiological characteristics of and risk factors for breast cancer in the world.

Authors:  Zohre Momenimovahed; Hamid Salehiniya
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-04-10

Review 5.  Oral Contraceptive Use and Breast Cancer Risk According to Molecular Subtypes Status: A Systematic Review and Meta-Analysis of Case-Control Studies.

Authors:  Agnieszka Barańska; Joanna Dolar-Szczasny; Wiesław Kanadys; Wiktoria Kinik; Dorota Ceglarska; Urszula Religioni; Robert Rejdak
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

6.  Risk factors for breast cancer subtypes among Black women undergoing screening mammography.

Authors:  Tara M Friebel-Klingner; Sarah Ehsan; Emily F Conant; Despina Kontos; Susan M Domchek; Anne Marie McCarthy
Journal:  Breast Cancer Res Treat       Date:  2021-08-03       Impact factor: 4.872

7.  Insights into the Behavior of Triple-Negative MDA-MB-231 Breast Carcinoma Cells Following the Treatment with 17β-Ethinylestradiol and Levonorgestrel.

Authors:  Sebastian Simu; Iasmina Marcovici; Amadeus Dobrescu; Daniel Malita; Cristina Adriana Dehelean; Dorina Coricovac; Flavius Olaru; George Andrei Draghici; Dan Navolan
Journal:  Molecules       Date:  2021-05-08       Impact factor: 4.411

8.  Effect of age at first use of oral contraceptives on breast cancer risk: An updated meta-analysis.

Authors:  Li-Wei Ji; Chun-Xia Jing; Su-Lian Zhuang; Wei-Cheng Pan; Xing-Po Hu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

9.  The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients.

Authors:  Mehdi Dehghani; Pedram Keshavarz; Abdolrasoul Talei; Majid Akrami; Sedighe Tahmasebi; Akbar Safaie; Maryam Ghanbari
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01

10.  Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.

Authors:  Lieske H Schrijver; Thea M Mooij; Anouk Pijpe; Gabe S Sonke; Marian J E Mourits; Nadine Andrieu; Antonis C Antoniou; Douglas F Easton; Christoph Engel; David Goldgar; Esther M John; Karin Kast; Roger L Milne; Håkan Olsson; Kelly-Anne Phillips; Mary Beth Terry; John L Hopper; Flora E van Leeuwen; Matti A Rookus
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.